It seems that some of us might have turned into amateur epidemiologists. We think we…
Tough times have caused the value of these three blue-chip companies to halve.
After two weeks of hunkering down, it seems the virus situation has yet to improve.
Things look awful right now, but patience is needed. Income investors should focus on businesses that can reward them in the long term, both in good and rough times.
What can investors expect from the transportation giant this year?
Remdesivir is one of the most promising treatments for COVID-19 that is undergoing trial testing.